噻托溴铵联合沙美特罗氟替卡松治疗慢性阻塞性肺疾病患者的疗效

Effect of Tiotropium Bromide Combined with Salmeterol Fluticasone in the Treatment of Patients with Chronic Obstructive Pulmonary Disease

目的探析慢性阻塞性肺疾病(COPD)患者应用噻托溴铵与沙美特罗氟替卡松联合治疗的临床效果。方法选取2018年3月至2020年1月雷州市人民医院急诊科收治的60例COPD患者作为研究对象,根据治疗方法不同分为单一组与联合组,每组30例。单一组应用沙美特罗氟替卡松治疗,联合组应用沙美特罗氟替卡松与噻托溴铵联合治疗。比较两组患者治疗前后肺功能指标水平、呼吸困难评分以及不良反应发生率。结果治疗后,两组第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC、FEV1占预计值百分比均较本组治疗前升高,且联合组FEV1(1.79±0.36)L、FVC(2.71±0.42)L、FEV1/FVC(66.05±4.51)%、FEV1占预计值百分比(67.62±5.72)%均高于单一组的(1.44±0.33)L、(2.32±0.41)L、(62.07±4.15)%、(59.61±5.34)%,差异有统计学意义(P<0.05)。治疗后,两组呼吸困难评分均较本组治疗前降低,且联合组呼吸困难评分(1.53±0.31)分低于单一组的(2.02±0.30)分,差异有统计学意义(P<0.05)。联合组不良反应发生率10.00%高于单一组的6.67%,但差异无统计学意义(P>0.05)。结论COPD患者应用噻托溴铵与沙美特罗氟替卡松联合治疗的临床效果确切,不仅可以改善患者肺功能,还可以缓解患者呼吸困难,安全可靠。

Objective To explore the effect of combined treatment of tiotropium bromide and salmeterol fluticasone in patients with COPD.Methods A total of 60 COPD patients admitted to the emergency department of Leizhou People's Hospital from March 2018 to January 2020 were selected as the research objects.According to different treatment methods,they were divided into single group and combined group,with 30 cases in each group.The single group was treated with salmeterol fluticasone,and the combined group was treated with salmeterol fluticasone and tiotropium bromide.The lung function index levels,dyspnea scores and the incidence of adverse reactions were compared between the two groups before and after treatment.Results After treatment,FEV1,FVC,FEV1/FVC,and the percentage of FEV1 in the predicted values of the two groups were all higher than those before the treatment,and the combined group FEV1(1.79±0.36)L,FVC(2.71±0.42)L,FEV1/FVC(66.05±4.51)%,FEV1 as a percentage of predicted value(67.62±5.72)%are higher than(1.44±0.33)L,(2.32±0.41)L,(62.07±4.15)%,(59.61±5.34)%of the single group,the difference was statistically significant(P<0.05).After treatment,the dyspnea scores of the two groups were lower than those before the treatment,and the dyspnea score(1.53±0.31)of the combined group was lower than(2.02±0.30)of the single group,P<0.05.The incidence of adverse reactions in the combined group was 10.00%,which is higher than 6.67%in the single group,but P>0.05.Conclusion The combination of tiotropium bromide and salmeterol fluticasone in patients with COPD has a definite clinical effect.It can not only improve the lung function of the patient,but also relieve the patient's breathing difficulties,and it's safe and reliable.